LUCY SCIENTIFIC DISCOVERY INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7597 USD | -12.68% |
|
-32.17% | -70.33% |
Financials (USD)
| Sales 2022 | - | Sales 2023 | 0.01 | Capitalization | 18.79M |
|---|---|---|---|---|---|
| Net income 2022 | -5M | Net income 2023 | -8M | EV / Sales 2022 * | - |
| Net Debt 2022 | 4.77M | Net Debt 2023 | 115K | EV / Sales 2023 | 2,682,682,605 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-1.63
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.61% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -12.68% | ||
| 1 week | -32.17% | ||
| Current month | -45.42% | ||
| 1 month | -42.88% | ||
| 3 months | -68.32% | ||
| 6 months | -73.53% | ||
| Current year | -70.33% |
1 week
0.72
1.15
1 month
0.721.45
Current year
0.722.84
1 year
0.7217.00
3 years
0.7240.00
5 years
0.7240.00
10 years
0.7240.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Nanula
CEO | Chief Executive Officer | 63 | 22-01-31 |
Brian Zasitko
DFI | Director of Finance/CFO | 44 | 21-10-31 |
Assad Kazeminy
CTO | Chief Tech/Sci/R&D Officer | 73 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Nanula
CEO | Chief Executive Officer | 63 | 22-01-31 |
Charles Nemeroff
BRD | Director/Board Member | 74 | 21-10-31 |
Livio Susin
BRD | Director/Board Member | 69 | 17-08-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.7597 | -12.68% | 71,242 |
| 24-04-25 | 0.87 | -3.12% | 79,385 |
| 24-04-24 | 0.898 | -14.48% | 39,586 |
| 24-04-23 | 1.05 | -7.08% | 20,869 |
| 24-04-22 | 1.13 | +0.89% | 6,759 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotes
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -70.33% | 1.34M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- LSDI Stock
